AN2 TherapeuticsANTX -2.69%22 EV-to-FCF is -2.68 as of Jul. 01, 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 331 Biotechnology companies, AN2 Therapeutics ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AN2 Therapeutics's Enterprise Value is $83.99 Mil.
AN2 Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-31.28 Mil. Therefore, AN2 Therapeutics's EV-to-FCF for today is -2.68.
The historical rank and industry rank for AN2 Therapeutics's EV-to-FCF or its related term are showing as below:
ANTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.03 Med: 0 Max: 0
Current: -2.68
ANTX's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs ANTX: -2.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AN2 Therapeutics's PE Ratio (TTM) for today is calculated as:
AN2 Therapeutics's share price for today is $4.703.
AN2 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AN2 Therapeutics EV-to-FCF Related Terms
AN2 Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for AN2 Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AN2 Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's EV-to-FCF falls into.
AN2 Therapeutics's current Enterprise Value is $83.99 Mil.
AN2 Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (ANTX) has a EV-to-FCF of -2.68 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AN2 Therapeutics and its competitors. According to the industry distribution chart, AN2 Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry.
Is AN2 Therapeutics' EV-to-FCF too high?
AN2 Therapeutics' current EV-to-FCF is -2.68. Based on the distribution chart, AN2 Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' EV-to-FCF compare to OKUR and KRRO?
According to the Biotechnology industry distribution chart, AN2 Therapeutics ranks #999999 out of 331 companies for EV-to-FCF. This places AN2 Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AN2 Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AN2 Therapeutics's current EV-to-FCF is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current EV-to-FCF of -2.68. The current EV-to-FCF is -2.68. AN2 Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current EV-to-FCF is -2.68 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score
Get the complete analysis for ANTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANTX has been successfully added to your 
